FDAnews Announces — Impact of GDUFA Performance Metrics on ANDA Approval Times: Opportunities, Risks and Practical Considerations Webinar, Sept. 23, 2014
Falls Church, VA (PRWEB) August 22, 2014 -- Impact of GDUFA Performance Metrics on ANDA Approval Times:
Opportunities, Risks and Practical Considerations
**FDAnews Webinar**
Sept. 23, 2014 — 1:30 p.m. – 3:00 p.m. EDT
http://www.fdanews.com/GDUFAimpact
For generic drugmakers, Oct. 1 is crunch time and is the date after which all ANDA amendment and prior-approval supplement applications must meet new performance goals under the Generic Drug User Fee Amendments (GDUFA) of 2012.
FDAnews has enlisted the assistance of Lachman Consulting’s Joan Janulis, a Hatch-Waxman pro and all-around expert on FDA regulation in the generic drug industry. She’ll help attendees read between the lines of the GDUFA performance metrics, associated guidance documents and MAPPs, and provide a roadmap to the post-GDUFA paradigm.
But make no mistake: this session is about much more than theory and abstraction. Attendees will discover concrete examples that illustrate what ANDA sponsors can expect and must prepare for.
In 90 fast-paced minutes, Ms. Janulis takes attendees from the big picture to nuts-and-bolts implementation. Here’s a point-by-point summary of what she’ll cover:
• Understanding how overarching GDUFA performance goals relate to ANDA reviews
• Identifying ANDA applications not subject to statutorily prescribed performance goals and how the FDA will handle these
• Impact of ANDA amendments (not to be underestimated!)
• Strategic opportunities and concealed risks associated with GDUFA
• “Standard industry practices” that could trip drugmakers up in the new GDUFA era
• Show-and-tell based on Lachman Consultants’ experience that steer drugmakers to higher application success rates under the new guidances
• And much more
With time so short before GDUFA full implementation, every second of advance preparation pays off in faster drug approvals and fewer hassles.
Meet the Presenter:
Joan Janulis is Vice President and Regulatory Affairs Practice Head for Lachman Consultants, a pharmaceutical consultancy known for its expertise in the generic pharmaceutical space. Ms. Janulis is an authority on development, regulatory approval and post-approval lifecycle management of generic drugs, and boasts extensive knowledge of Hatch Waxman legislation and other FD&C Act amendments affecting generics. A 20-year veteran of the pharmaceutical industry, she has experience at Purepac Pharmaceuticals, F.H. Faulding and Co., IVAX Pharmaceuticals and Alpharma Inc. developing strategies to cut ANDA approval times and achieve favorable market entry position for new product launches.
Who Will Benefit:
• Executive management
• R&D
• Regulatory affairs
• Manufacturing/operations/supply chain management
• QA/QC
Webinar Details:
Impact of GDUFA Performance Metrics on ANDA Approval Times:
Opportunities, Risks and Practical Considerations
**FDAnews Webinar**
Sept. 23, 2014 — 1:30 p.m. – 3:00 p.m. EDT
http://www.fdanews.com/GDUFAimpact
Tuition:
$487 per site – includes webinar registration and audio cds and transcripts
Easy Ways to Register:
Online: http://www.fdanews.com/GDUFAimpact
By phone: 888-838-5578 or 703-538-7600
About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.
Michelle Butler, FDANEWS, http://www.fdanews.com, +1 (703) 538-7665, [email protected]
Share this article